SCHEMBL4696274

SCHEMBL4696274

O=S(=O)(Nc1ccc(Oc2cncc(Cl)c2)cc1)c1ccc(Cl)cc1

nearest known ligand 0.72

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PPARG P37231 9/20 0.72
PGR P06401 5/20 0.67
CES1 P23141 1/20 0.58
ALDH1A1 P00352 1/20 0.55
CYP3A4 P08684 2/20 0.54
MAPT P10636 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
CCR2 P41597 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4696087 0.84 PPARG (1.00) PPARGPGRCYP3A4
SCHEMBL4696116 0.81 PPARG (0.75) PPARGCYP3A4CCR2
SCHEMBL14031307 0.80 CYP19A1 (0.61) PPARGPGRALDH1A1MAPT
SCHEMBL4697352 0.80 PPARG (0.74) PPARGCYP3A4
SCHEMBL5801508 0.79 PGR (0.91) PGRCES1ALDH1A1MAPTNPSR1
SCHEMBL12584774 0.77 PPARG (0.63) PPARGALDH1A1CYP3A4MAPTCYP2C9
SCHEMBL14018270 0.77 PPARG (0.58) PPARGALDH1A1CYP3A4MAPT
SCHEMBL6554630 0.76 CES1 (1.00) PGRCES1ALDH1A1MAPT
SCHEMBL2474197 0.76 CES1 (1.00) PGRCES1ALDH1A1MAPT
SCHEMBL12584896 0.76 CCR2 (0.54) PPARGCYP3A4CYP2C9CYP2C19CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1053227-B1 PPAR-GAMMA MODULATORS AMGEN INC (US) 2008-11-05 EP disclosed
US-7439242-B2 PPARγ modulators AMGEN INC. (US) 2008-10-21 US disclosed
US-7439242-B2 PPARγ modulators AMGEN INC. (US) 2008-10-21 US disclosed
US-7439242-B2 PPARγ modulators AMGEN INC. (US) 2008-10-21 US disclosed
US-6620827-B2 Peroxisome proliferator-activated receptors-gamma to control lipid metabolism ane obesity; antidiabetic, -inflammatory and -arthritic agents; non-insulin dependent diabetes; antilipemic and -cholesterol agents TULARIK INC. 2003-09-16 US disclosed
US-20030088103-A1 PPARgamma modulators TULARIK INC. (US) 2003-05-08 US disclosed
US-20010027200-A1 PPARgamma modulators TULARIK INC. 2001-10-04 US disclosed
US-6200995-B1 PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY TULARIK INC. 2001-03-13 US disclosed
EP-1053227-A1 PPAR-GAMMA MODULATORS TULARIK, INC. (US) 2000-11-22 EP disclosed
WO-1999038845-A1 PPAR-GAMMA MODULATORS TULARIK INC. (US) 1999-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030088103-A1 PPARgamma modulators PPARG, PPARA, PPARD PPARG 1/4885PGR 588/4885CES1 286/4885
US-20010027200-A1 PPARgamma modulators PPARG, PPARA, PPARD PPARG 1/4885PGR 588/4885CES1 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.